Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.

IF 4.2 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2026-09-28 DOI:10.1007/s13300-026-01915-y

Shanshan Wang, Bixuan Dong, Zewei Shen

{"title":"Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.","authors":"Shanshan Wang, Bixuan Dong, Zewei Shen","doi":"10.1007/s13300-026-01915-y","DOIUrl":null,"url":null,"abstract":"Introduction: Real-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR. This post hoc analysis investigated the use of combination semaglutide-sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment, glycated hemoglobin (HbA1c) changes, and safety in a subset of SCHOLAR participants.Methods: Participants from SCHOLAR were included in this post hoc, single-arm analysis if they were prescribed once-weekly subcutaneous semaglutide and had ≥ 1 SGLT2i prescription within 6 months of initiating semaglutide. Participants were grouped according to whether semaglutide use was continuous or not and by baseline HbA1c (≥ 7%). We evaluated the proportion of SCHOLAR participants prescribed combined semaglutide-SGLT2i. Key endpoints were: change in HbA1c from baseline to month 6; proportion of participants achieving a HbA1c level < 7% at month 6; change in lipid profile from baseline to month 6; and safety profile of combined semaglutide-SGLT2i.Results: A total of 11,361 (42.3%) SCHOLAR participants were treated with combined semaglutide-SGLT2i. Mean change in HbA1c (95% confidence interval [CI]) from baseline to month 6 was - 0.64%-points (- 0.71, - 0.56) (p < 0.0001) for the overall combined semaglutide-SGLT2i group. The greatest change was seen in the continuous semaglutide group with baseline HbA1c ≥ 7% (- 1.20%-points [95% CI - 1.36, - 1.04]). The proportion of participants with HbA1c levels < 7% increased from 37.8% at baseline to 55.1% at month 6 for the overall combined treatment group. There were significant reductions in mean total cholesterol (p < 0.0001), low-density lipoprotein cholesterol (p < 0.0001), and triglycerides (p = 0.0043) as well as a significant increase in high-density lipoprotein cholesterol (p < 0.0001). Gastrointestinal adverse events were most frequent.Conclusions: Combined semaglutide-SGLT2i treatment was prevalent in this subset of the SCHOLAR population and associated with significant reduction in HbA1c and changes in lipid profile. The safety profile of combined semaglutide-SGLT2i was similar to the overall SCHOLAR population.Trial registration number: NCT06351748.","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-026-01915-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Real-world use of once-weekly semaglutide in adults with type 2 diabetes in China has been shown in SCHOLAR. This post hoc analysis investigated the use of combination semaglutide-sodium-glucose cotransporter-2 inhibitor (SGLT2i) treatment, glycated hemoglobin (HbA1c) changes, and safety in a subset of SCHOLAR participants.

Methods: Participants from SCHOLAR were included in this post hoc, single-arm analysis if they were prescribed once-weekly subcutaneous semaglutide and had ≥ 1 SGLT2i prescription within 6 months of initiating semaglutide. Participants were grouped according to whether semaglutide use was continuous or not and by baseline HbA1c (≥ 7%). We evaluated the proportion of SCHOLAR participants prescribed combined semaglutide-SGLT2i. Key endpoints were: change in HbA1c from baseline to month 6; proportion of participants achieving a HbA1c level < 7% at month 6; change in lipid profile from baseline to month 6; and safety profile of combined semaglutide-SGLT2i.

Results: A total of 11,361 (42.3%) SCHOLAR participants were treated with combined semaglutide-SGLT2i. Mean change in HbA1c (95% confidence interval [CI]) from baseline to month 6 was - 0.64%-points (- 0.71, - 0.56) (p < 0.0001) for the overall combined semaglutide-SGLT2i group. The greatest change was seen in the continuous semaglutide group with baseline HbA1c ≥ 7% (- 1.20%-points [95% CI - 1.36, - 1.04]). The proportion of participants with HbA1c levels < 7% increased from 37.8% at baseline to 55.1% at month 6 for the overall combined treatment group. There were significant reductions in mean total cholesterol (p < 0.0001), low-density lipoprotein cholesterol (p < 0.0001), and triglycerides (p = 0.0043) as well as a significant increase in high-density lipoprotein cholesterol (p < 0.0001). Gastrointestinal adverse events were most frequent.

Conclusions: Combined semaglutide-SGLT2i treatment was prevalent in this subset of the SCHOLAR population and associated with significant reduction in HbA1c and changes in lipid profile. The safety profile of combined semaglutide-SGLT2i was similar to the overall SCHOLAR population.

Trial registration number: NCT06351748.

查看原文本刊更多论文

中国成人糖尿病患者联合使用西马鲁肽和钠-葡萄糖共转运蛋白2抑制剂和代谢结局：事后分析。

导读：学者研究显示，中国成人2型糖尿病患者每周使用一次西马鲁肽。这项事后分析调查了在一部分SCHOLAR参与者中联合使用semaglu肽-钠-葡萄糖共转运蛋白-2抑制剂（SGLT2i）治疗、糖化血红蛋白（HbA1c）变化和安全性。方法：来自SCHOLAR的参与者被纳入这项事后单组分析，如果他们每周服用一次皮下注射西马鲁肽，并且在开始服用西马鲁肽的6个月内服用了≥1次SGLT2i处方。参与者根据是否连续使用西马鲁肽和基线HbA1c（≥7%）进行分组。我们评估了联合使用semaglutide-SGLT2i的SCHOLAR参与者的比例。关键终点为：HbA1c从基线到第6个月的变化；结果：共有11,361名（42.3%）SCHOLAR参与者接受了semaglutide-SGLT2i联合治疗。从基线到第6个月，HbA1c的平均变化（95%置信区间[CI]）为- 0.64%点（- 0.71,- 0.56）(p)。结论：semaglutide-SGLT2i联合治疗在SCHOLAR人群的这一亚群中普遍存在，并且与HbA1c的显著降低和血脂变化相关。semaglutide-SGLT2i联合用药的安全性与SCHOLAR总体人群相似。试验注册号：NCT06351748。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.